Amylyx Pharmaceuticals Cash Flow Statement (2021-2026) | AMLX

Cash Flow Statement Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating Activities
Net Income (Quarter)
-21.92M-23.14M-28.32M-47.85M-54.09M-53.76M-42.70M1.57M22.07M20.89M2.70M-118.79M-72.70M-72.70M-36.94M-35.91M-41.44M-34.39M111.58M-41.21M
Depreciation and Depletion (Quarter)
0.01M0.01M0.02M0.04M0.10M0.17M0.18M0.20M0.28M0.30M0.30M0.32M0.21M0.22M0.16M0.16M0.14M0.12M0.11M0.10M
Share-based Compensation (Quarter)
0.66M0.80M1.09M4.39M5.71M5.52M6.09M7.50M9.95M10.18M9.53M9.92M9.57M6.80M6.74M6.83M7.35M7.08M6.39M6.12M
Gains from Sales and Divestitures (Quarter)
0.15M0.16M0.17M0.19M0.23M0.26M0.69M0.71M0.70M0.78M1.16M1.20M0.68M
Gains from Investment Securities (Quarter)
-1.90M4.40M1.70M8.99M0.01M3.97M14.23M10.06M2.40M0.27M25.58M0.36M10.74M4.39M-0.13M0.10M2.32M2.43M-0.70M3.16M
Non-cash Items (Quarter)
15.63M1.77M1.39M1.79M201.76M127.49M3.17M44.55M27.64M4.74M5.15M3.86M3.58M4.09M13.88M52.57M42.97M5.56M
Change in Interest Receivables (Quarter)
0.00M0.01M0.05M-0.55M-0.25M0.61M-0.73M0.35M-0.12M-0.30M0.12M-0.06M-0.07M-0.01M0.06M-0.01M
Cash from Operations (Quarter)
-13.05M-20.86M-28.24M-40.63M-46.46M-43.08M-49.70M-5.07M8.61M-5.17M13.55M-0.49M-66.58M-41.57M-59.01M-39.82M-25.25M-30.37M-27.90M-36.88M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles (Quarter)
-0.10M-0.00M0.11M0.09M1.86M2.90M1.98M2.48M2.57M2.58M3.18M2.31M1.79M1.70M1.52M1.24M1.06M0.61M
Depreciation & Amortization (CF) (Quarter)
0.01M0.01M0.02M0.04M0.10M0.17M0.18M0.20M0.28M0.30M0.30M0.30M0.20M0.20M0.20M0.20M0.10M0.10M0.10M0.10M
Change in Working Capital
Change in Receivables (Quarter)
15.17M2.25M15.92M-4.12M10.70M-19.70M-16.26M-2.36M-1.28M-0.15M-0.20M0.03M-0.04M
Change in Inventory (Quarter)
9.21M13.30M19.33M14.01M26.48M9.25M
Change in Account Payables (Quarter)
-1.05M0.16M1.39M5.02M-1.26M-1.10M-0.80M4.61M13.84M-18.39M15.82M-0.65M-16.43M-3.49M1.47M1.87M-1.53M-0.03M0.28M0.01M
Change in Accured Expenses (Quarter)
2.74M2.04M5.65M2.18M-1.21M-0.15M20.77M-7.78M-12.53M-13.11M-26.39M-11.88M5.40M1.09M-1.21M-6.67M
Investing Activities
Capital Expenditures (Quarter)
0.15M0.19M0.34M1.10M0.46M0.62M0.25M0.28M0.36M0.36M0.07M0.09M-0.02M0.02M0.01M0.02M0.02M0.09M
Change in Acquisitions & Divestments (Quarter)
24.91M36.00M84.50M34.00M66.00M123.50M56.70M147.92M74.00M130.00M75.00M65.00M60.00M62.00M64.00M60.00M60.00M
Cash from Investing Activities (Quarter)
-49.21M2.81M-99.31M4.46M84.04M-228.18M55.99M123.22M-108.09M20.93M0.82M-28.96M38.82M64.98M-43.66M22.99M5.24M29.47M36.26M
Financing Activities
Other financing activities (Quarter)
0.95M
Debt Issuance and Repayment
Long-Term Debt Issuances (Quarter)
65.58M191.11M-0.38M
Change in Capital Stock
Shares Issued (Quarter)
0.00M0.16M0.14M200.90M-200.65M1.94M3.54M2.12M0.98M0.35M1.45M0.05M0.49M0.15M0.97M0.07M2.66M0.38M7.16M
Preferred Shares Issued (Quarter)
132.72M0.21M
Misc.
Cash from Financing Activities (Quarter)
1.99M131.65M-1.06M200.46M-0.83M232.16M1.04M1.38M0.89M0.23M0.13M0.03M0.08M0.11M65.66M-0.03M191.61M-0.21M3.22M
Exchange Rate Effect (Quarter)
0.00M0.01M-0.07M-0.14M-0.37M0.51M0.07M-0.02M-0.13M0.24M-0.11M-0.04M0.24M-0.53M0.20M0.61M0.15M0.12M-0.11M
Change in Cash (Quarter)
-11.05M61.58M-26.49M60.44M-42.96M40.59M-45.21M52.04M133.20M-112.50M34.94M0.35M-95.55M-2.44M5.56M-17.62M-1.68M166.62M1.48M2.49M
Free Cash Flow (Quarter)
-13.05M-21.02M-28.43M-40.98M-47.57M-43.54M-50.32M-5.32M8.33M-5.53M13.20M-0.56M-66.67M-41.55M-59.03M-39.84M-25.27M-30.39M-27.99M-36.88M
Net Cash Flow (Quarter)
-11.05M61.58M-26.50M60.51M-42.83M40.96M-45.72M51.96M133.22M-112.37M34.71M0.46M-95.51M-2.67M6.08M-17.82M-2.29M166.47M1.36M2.60M